Key result
Narrative medicine analysis in patients with PAH treated with macitentan and/or selexipag aligned with emPHasis-10 scores, with 62% of patients describing PAH as manageable at 12 months.
Why the study?
Assessing the specific impact of pulmonary arterial hypertension on health-related quality of life, including patients' subjective experiences and caregiving burden, remains a key challenge.
How do patient and caregiver illness narratives align with emPHasis-10 health-related quality of life scores over 12 months in patients with pulmonary arterial hypertension treated with macitentan and/or selexipag?
Cohort (n=186)
Yes
How do patient and caregiver illness narratives align with emPHasis-10 health-related quality of life scores over 12 months in patients with pulmonary arterial hypertension treated with macitentan and/or selexipag?
Integrating narrative medicine with validated patient-reported outcomes (emPHasis-10) captures the emotional, social, and caregiving burdens of pulmonary arterial hypertension to support a holistic, patient-centred care pathway.
Answers are grounded in this paper and cite their sources.
Supports narrative medicine as adjunct to emPHasis-10 for PAH assessment; hypothesis-generating and leaves open prospective validation of outcomes.
Introduction A key challenge in pulmonary arterial hypertension (PAH) research is assessing the specific impact of this condition on health-related quality of life (HRQoL), also considering the patient’s subjective experience and caregiving burden. The prospective, observational, multicentre Non-INterventional Study on Pulmonary arterial hypertension patients treated with macitentan and/or selexipag: ExperienCe from an ITalIan cOhort (INSPECTIO) study integrated narratives with patient-reported outcomes (PROs) and clinical data to gain deeper insight into patients’ experiences of PAH, also involving caregivers’ perspectives. Methods The study was conducted across 29 Italian hospital-based centres and enrolled adult patients with PAH already on treatment with macitentan and/or selexipag as part of combination therapy. A dedicated narrative collection was carried out within the larger study. Patient and caregiver narratives were collected at enrolment (visit 1; V1) and at 12 months (visit 3; V3), then analysed through MAXQDA software and correlated with emPHasis-10 questionnaire scores and clinical data. Results Out of the 186 patients enrolled in the overall INSPECTIO study, 96/186 (52%) completed the narrative at V1 and 58/186 (31%) at V3; 29/54 (54%) caregivers completed the narrative at V1 and 16/54 (30%) at V3. The analysis revealed an alignment between patient narratives and emPHasis-10 scores. Specifically, at V3, emPHasis-10 scores were higher for patients who did not mention their domestic life in narratives, reported feelings of shame or isolation, limitations or breathlessness also in daily activities and reported ongoing treatment-related issues. Nonetheless, at V3, 36/58 (62%) of patients described living with PAH as manageable. The care pathway showed a positive impact on caregivers: their narratives indicated a shift from V1 to V3, with improved perceptions of the care relationship and PAH therapies. Conclusion INSPECTIO is the first study to integrate narratives, PROs and clinical data in PAH research. Findings suggested that appropriate support and therapeutic management are crucial to help patients cope with the condition. Narratives have proven to be a valuable tool for understanding the impact of PAH and improving its management, providing insights that can inform a more patient-centred approach. Trial registration number NCT04567602 .
No takes yet. Share an insight, caveat, or question.
Scelsi et al. (2026) conducted a cohort in Pulmonary arterial hypertension (PAH) (n=186). Narrative medicine integration in patients with PAH treated with macitentan and/or selexipag was evaluated on Patient and caregiver illness narratives and correlation with emPHasis-10 (e10) health-related quality of life questionnaire scores at 12 months. Narrative medicine analysis in patients with PAH treated with macitentan and/or selexipag aligned with emPHasis-10 scores, with 62% of patients describing PAH as manageable at 12 months.
Synapse has enriched 10 related papers. Consider them for comparative context: